SCNXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Scienture Holdings, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$2.92−0.44 (-13.10%)
Close on Oct 19, 2026
- Market cap
- $115.68M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$10.46 (−78.17%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.EarningsSplit
Scienture Holdings, Inc. grew revenue 215.9% to $431.61K over fiscal 2025.
Revenue
$431.61K
+215.9% vs. a year earlier
Operating income
-$40.07M
TTM Q2 2026
EPS, diluted
-$1.85
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Jun 30, 2026
Valuation
- Market cap
- $115.68M
- P/E ratio
- –
- Price to sales
- 268.02
- Price to book
- 1.80
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $431.61K
- Net income
- -$37.95M
- EPS, diluted
- -$1.85
- Book value per share
- $1.62
- Diluted shares
- 40M
Fourteen years at a glance
Fiscal years 2012 to 2025 and trailing twelve months, USD
Revenue
–
Gross profit
$720.44K+9660.7% YoY
Operating income
-$40.07M
Net income
-$37.95M
EPS, diluted
-$1.85
Free cash flow
–
Reported periodTrailing twelve months